Cancer Archives

Kintor Pharmaceutical drug gets positive results for breast cancer

News and Trends 29 Sep 2022

Positive results from study of drug to treat patients with breast cancer published

Results from a phase 1b study of a drug to treat patients with androgen receptor positive (AR+) metastatic breast cancer (mBC) in China were published yesterday (September 28). Kintor Pharmaceutical Limited, a clinical stage biotech company has developed Pruxelutamide, an oral new generation AR antagonist which has shown promising activity in heavily pretreated AR+ mBC […]

September 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 28 Sep 2022

Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies

Scribe Therapeutics has entered into an agreement with Sanofi which will allow Sanofi use of its CRISPR genome editing technologies. Scribe Therapeutics’ custom genome editing and delivery tools called CasX-Editors (XE) based on foundations such as the CasX enzyme will enable genetic modification of natural killer (NK) cell therapies for cancer and will support Sanofi’s […]

September 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Sep 2022

Pheon Therapeutics launches with $68M in series A funding for treatment of solid tumors

Pheon Therapeutics launched today (September 28) following the closing of a $68 million series A funding back in March. The investment will allow antibody-drug conjugate (ADC) specialist Pheon to advance its lead ADC program to clinical proof-of-concept and establish of novel ADCs. The financing was led by Brandon Capital, Forbion and Atlas Venture, with participation […]

September 28, 2022 - 3 minutesmins - By Liza Laws

Cleara Biotech closes $2.5M round for senescence treatment

News and Trends 28 Sep 2022

Cleara Biotech closes $2.5M seed financing round to progress senescence treatment

Cleara Biotech has closed a $2.5 million seed financing round that it will use for progress its compounds toward clinical development. The company that develops therapies for treating different pathologies of scarred cellular senescence including late-stage cancer and chronic diseases made the announcement yesterday (September 27). The financing round earlier in the year was led […]

September 28, 2022 - 4 minutesmins - By Liza Laws

CAR-T cell therapy, cancer therapy, cell therapy

News and Trends 27 Sep 2022

Bioheng Biotech has positive CAR-T cell therapy results published in academic journal

Positive results from a phase 1 clinical study of RD13-01, an anti-CD7 universal CAR-T therapy product, have been published in reputable academic journal, Cell Research. China-based Bioheng Biotech Co. Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy made the announcement today (September 27). The results published with the title of ‘CD7-targeted allogeneic CAR-T […]

September 27, 2022 - 3 minutesmins - By Liza Laws

kai pinkernell glycostem nk cell therapy

Interview 27 Sep 2022

Natural killer cells: a thriving frontier in allogeneic cell therapy

Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could usher in off-the-shelf cancer immunotherapies. Since their first approvals in 2017, chimeric antigen receptor (CAR)-T cell immunotherapies have showcased the potential of immuno-oncology in providing long-lasting treatments for cancer. This impact was felt in not just the CAR-T cell therapy […]

September 27, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 27 Sep 2022

Angel Pharma announces approval of IND application for clinical trial of mupadolimab

Approval of an investigational new drug (IND) application for mupadolimab has been granted by the Center for Drug Evaluation (CDE) to initiate a phase 1/1b clinical trial in China. Angel Pharma, a clinical stage biopharmaceutical company owns the rights to mupadolimab in Greater China. Mupadolimab is a humanized monoclonal antibody directed against CD73. In preclinical […]

September 27, 2022 - 2 minutesmins - By Liza Laws

Using the power of proteomics to predict immunotherapy responses in melanoma and beyond

Next-generation proteomics has a vital role to play in the search for new biomarkers of immunotherapy response. Recent studies in melanoma presented at the European Society for Medical Oncology (ESMO) Congress highlight how these insights have the potential to transform cancer care. The recent success of immunotherapies that manipulate the patient’s immune system to recognize […]

September 27, 2022 - 6 minutesmins - By External Contributor

News and Trends 26 Sep 2022

TILT and MSD working on immunotherapy trial for non-small cell lung cancer

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA (pembrolizumab), MSD’s anti-PD-1 therapy. The […]

September 26, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Sep 2022

Grant awarded to help bring to market an innovative treatment for bone cancer

A grant has been awarded to look into the feasibility of bringing to market a new therapy to treat osteosarcoma that aids bone regeneration with fewer side-effects. The European Research Council gave the Proof of Concept grant to professor Cristina Canal from the Technical University of Catalunya’s (UPC) department of materials science and engineering who […]

September 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Sep 2022

Knockback for drug to treat patients with relapsed or refractory multiple myeloma

A Swedish biotech company says it believes its treatment could be the ‘canary in the coalmine’ despite a knockback. The Oncologic Drugs Advisory Committee (ODAC) has said it does not consider the treatment for patients with relapsed or refractory multiple myeloma (RRMM) favorable in a benefit-risk profile. Oncopeptides AB has been trialing Pepaxto in the […]

September 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Sep 2022

Beyond Biotech podcast 15: Cullinan Oncology, Pleco Therapeutics, TikoMed

This week’s podcast has three guests. In honor of World Cancer Research Day on September 24, we have an overview of cancer research with Nadim Ahmed, CEO of Cullinan Oncology; a chat with Ivo Timmermans, CEO of Pleco Therapeutics; and talk with Anders Kristensson, CEO of TikoMed. We also have our weekly chat with global […]

September 23, 2022

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Subscribe to our newsletter

Advertise with us

Cancer

Positive results from study of drug to treat patients with breast cancer published

Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies

Pheon Therapeutics launches with $68M in series A funding for treatment of solid tumors

Cleara Biotech closes $2.5M seed financing round to progress senescence treatment

Bioheng Biotech has positive CAR-T cell therapy results published in academic journal

Natural killer cells: a thriving frontier in allogeneic cell therapy

Angel Pharma announces approval of IND application for clinical trial of mupadolimab

Using the power of proteomics to predict immunotherapy responses in melanoma and beyond

TILT and MSD working on immunotherapy trial for non-small cell lung cancer

Grant awarded to help bring to market an innovative treatment for bone cancer

Knockback for drug to treat patients with relapsed or refractory multiple myeloma

Beyond Biotech podcast 15: Cullinan Oncology, Pleco Therapeutics, TikoMed

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!